Drug intelligence / Profile preview

NL-17

Development stage: Preclinical
Lead developer: Neurocarrus
Modality: Recombinant Proteins and Enzymes

Overview

NL-17 is an engineered recombinant protein biologic currently in preclinical development by Neurocarrus for the prevention of migraine. The therapeutic is designed to specifically target sensory neurons to control migraine pain signaling. By modulating the activity of these neurons, NL-17 aims to provide a targeted approach to migraine management, potentially offering a long-acting solution with a favorable safety profile by minimizing off-target effects in the central nervous system or other tissues.

Beyond the preview

Go deeper on NL-17.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NL-17.

Explore the full profile